Fragile histidine triad (FHIT) and p53 gene inactivaton as response markers in non-small-cell lung cancer (NSCLC) patients treated with platinum-analogue regimen: Retrospective analysis

被引：0
|
作者：
Cortinovis, Diego
Bajetta, Emilio
Sozzi, Gabriella
Mariani, Luigi
Fabbri, Alessandra
Livio, Anna
Roz, Luca
Formisano, Barbara
Zilembo, Nicoletta
Bidoli, Paolo
机构：
[1] Ist Nazl Studio & Cura Tumori, Med Oncol Unit 2, I-20133 Milan, Italy
[2] Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy
[3] Ist Nazl Studio & Cura Tumori, Stat Med Dept, I-20133 Milan, Italy
[4] Ist Nazl Studio & Cura Tumori, Anat Pathol Unit, I-20133 Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：253 / 253
页数：1
相关论文
共 50 条
  • [41] Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer
    Lin, Sheng
    Li, Xiaoqin
    Lin, Ming
    Yue, WenXiang
    MEDICINE, 2021, 100 (05) : E24194
  • [42] RETROSPECTIVE ANALYSIS OF CLINICAL FEATURES OF 5-YEAR-SURVIVAL PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Hirashima, T.
    Okamoto, N.
    Suzuki, H.
    Morishita, N.
    Tamiya, M.
    Shiroyama, T.
    Kondoh, Y.
    Ryota, N.
    Kawase, I.
    ANNALS OF ONCOLOGY, 2012, 23 : 113 - 113
  • [43] Paclitaxel (P) and carboplatin (C) combination for the treatment of patients with advanced non-small-cell lung cancer (NSCLC): an effective and well tolerated regimen
    Moreno-Vega, AL
    Aranda-Bellido, F
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 411 - 411
  • [44] K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer
    Y Fukuyama
    T Mitsudomi
    K Sugio
    T Ishida
    K Akazawa
    K Sugimachi
    British Journal of Cancer, 1997, 75 : 1125 - 1130
  • [45] Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis
    Yaru Tian
    Hairong Tian
    Xiaoyang Zhai
    Hui Zhu
    Jinming Yu
    Frontiers of Medicine, 2022, 16 : 610 - 617
  • [46] Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis
    Tian, Yaru
    Tian, Hairong
    Zhai, Xiaoyang
    Zhu, Hui
    Yu, Jinming
    FRONTIERS OF MEDICINE, 2022, 16 (04) : 610 - 617
  • [47] Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis
    Tian Yaru
    Tian Hairong
    Zhai Xiaoyang
    Zhu Hui
    Yu Jinming
    Frontiers of Medicine, 2022, 16 (04) : 610 - 617
  • [48] K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer
    Fukuyama, Y
    Mitsudomi, T
    Sugio, K
    Ishida, T
    Akazawa, K
    Sugimachi, K
    BRITISH JOURNAL OF CANCER, 1997, 75 (08) : 1125 - 1130
  • [49] P53 Her2/neu as prognostic factors in advanced non-small cell lung cancer (NSCLC) treated with paclitaxel
    Yumuk, R
    Turhal, N
    Ahiskali, R
    Gumus, M
    Hatabay, N
    Turken, O
    Ozkan, A
    Salepci, T
    Aliustaoglu, M
    LUNG CANCER, 2005, 49 : S152 - S152
  • [50] Genetic analysis of cytidine deaminase (CDA) for the prediction of response to chemotherapy and survival in advanced non-small-cell lung cancer (NSCLC) patients treated with gemcitabine
    Vasile, Enrico
    Giovannetti, Elisa
    Tibaldi, Carmelo
    Mey, Valentina
    Nannizzi, Sara
    Stasi, Irene
    Danesi, Romano
    Del Tacca, Mario
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2006, 17 : 256 - 256
12345